136 results about "Mice brain" patented technology

The invention relates to bifidobacterium breve CCFM1025, a fermented food and application thereof. The bifidobacterium breve CCFM1025 can be used for improving the depression-like behavior of a depression mouse, improving 5-hydroxytryptamine in the brain of the depression mouse, improving the level of 5-hydroxytryptamine and a brain-derived neurotrophic factor, reducing the level of corticosteronein serum of the depression mouse, improving the level of 5-hydroxytryptamine in the serum of the depression mouse, improving intestinal flora disturbance of the depression mouse, reducing the abundance of intestinal veillonella, improving the abundance of bifidobacterium and mycoplasmataceae, improving alpha-diversity of intestinal flora and reducing occurrence of inflammatory bowel disease and obesity. By adopting the bifidobacterium breve CCFM1025, the mRNA level of tryptophan hydroxylase in a simulated entero-chromaffin cell can be improved, the secretion volume of 5-hydroxytryptophane ofthe cell can be improved, and a precursor substance is specifically provided to synthesis of 5-hydroxytryptamine in the brain. The bifidobacterium breve CCFM1025 has a wide application prospect.

The invention discloses a PEGylated scutellarin compound and a preparation method thereof. The PEGylated scutellarin compound is as the shown formula (IV) and the PEGylated scutellarin compound can be applied to preparing medicaments applied to treating cerebral thrombosis, cerebral infarction, cerebral apoplexy, sequelaes caused by cerebral apoplexy, coronary heart disease or angina. Compared with the original scutellarin compound, the water solubility of the scutellarin compound is increased obviously; simultaneously, pharmacodynamics experiment on the mice model of cerebral ischemia-reperfusion shows that: compared with the original medicament, the biological activity of the scutellarin promedicament is strengthened obviously.

The present invention is one kind of red peony injection prepared with red peony root as material and through alcohol extraction, n-butanol extraction or macroporous resin purification, and adding proper amount of medicinal supplementary material and injection water. It is stable and may be used in intramuscular injection, intravenous injection and intravenous instillation. Pharmacodynamic experiment shows that the medicine of the present invention can improve the behavior disorder of rat with cerebral infarction obviously, reduce the area of cerebral infarction, decrease water content in infracted brain tissue, reduce the peroxidation damage of lipoid in brain tissue and raise the acute oxygen lack tolerance of mouse and thus has excellent treat effect on cerebral infarction.

The invention discloses an application of ganoderic acid A to preparation of drugs for activating brain CD4+T cells and inhibiting neuroinflammation. Experiments show that the ganoderic acid A significantly up-regulates the content of CD4+T in mouse brains, reduces the levels of L-1beta, IL-6, TNF-alpha, NF-kB and the like, and down-regulates expression of Abeta1-42, p-Tau, APOE, IBA-1, and GFAP,which suggests that the ganoderic acid A can activate the CD4+T cells in brains and inhibit neuroinflammation. Acute toxicity experiments on cells and animals show that the safe dose range of the ganoderic acid A is wide, and can be applied to preparation of the drugs for activating the CD4+T cells in brains and inhibiting neuroinflammation.

Comprehensive analysis of transcription control factor complexes in a mouse brain cDNA library with c-Jun as a bait by using the cotranslation selection and screening of in vitro virus (IVV) and the C-terminal labeling method are conducted, thereby to provide known and unknown proteins which are unknown to form a complex with the c-Jun protein, whereby proteins that interact with c-Jun, nucleic acids encoding them and inhibitors utilizing them as well as methods for detecting an interaction and screening methods are provided.

The invention relates to a sample preparation method for mice brain tissue proteome analysis. The method comprises the following steps: (1) replacing the blood through apex perfusion, namely, narcotizing a mice, performing slow apex perfusion, stopping while the liver is in grey white, and taking out a brain tissue; (2) extracting protein, namely, grinding the brain tissue into powder, adding a pre-cooled Tris buffer solution, ultrasonically treating, incubating in a shaking table, and centrifuging to obtain a protein extracting solution I; (3) thermally treating to increase protein solubility, namely, mixing the protein extracting solution I and the thermally treated solution, treating for 5min, and centrifuging to obtain the protein extracting solution II; (4) precipitating to remove fat, namely, adding the protein extracting solution II in the pre-cooled fat-removing precipitation solution CUS, precipitating, centrifuging, washing, and drying to obtain purified protein powder; and (5) re-dissolving the protein, namely, adding the purified protein powder in an urea protein lysate, and centrifuging to obtain a proteome sample. With the sample preparation method disclosed by the invention, blood and fat influences of the brain tissue of the mice can be economically and efficiently removed, and the solubility of the protein sample is increased.

The invention provides a chemical heredity epilepsy persistent state disease animal model and a construction method and application thereof. The epilepsy persistent state disease animal model is a mouse brain kernel group (a hippocampus CA1 region and a thalamus anterior nucleus VA region of a model I); injecting a brain stereotaxic virus (a chemical genetic virus rAAV-CaMKIIa-hM3D (Gq)-mCherry-WPREs-pA) in an apricot kernel BLA region and a thalamus anterior nucleus VA region on the outer side of a substrate of the model II, and embedding an electrode array in a mouse hippocampus CA3 region;after the mouse is recovered for one week, a metabolite CNO of clozapine is injected into the abdominal cavity so that the CNO is combined with a virus expression receptor, neurons are activated to induce epileptic persistent state attack, and the epilepsy persistent state disease animal model is obtained through behavioral observation and in-vivo multichannel local field potential recording judgment. The epilepsy persistent state disease animal model constructed by the method is stable in seizure duration, high in success rate, low in death rate and good in repeatability, and has important significance in researching the origin and formation mechanism of epilepsy persistent state, and screening and mechanism of drug-resistant epilepsy persistent state drugs.

The invention provides a double-color fluorescent probe as well as a synthesis method and application thereof, the double-color fluorescent probe is especially suitable for simultaneously detecting O2. <-> and Zn < 2 + > in a living body, the double-color fluorescent probe is composed of dipyridylmethylamine(DPA), caffeic acid and 4-bromo-1, 8-naphthoic anhydride, the double-color fluorescent probe has the advantages of simple preparation, sensitive detection, good selectivity and the like. According to the method, the change of the O2. <-> and Zn < 2 + > in the brain of the mouse with depression is successfully imaged and analyzed at the living body level for the first time, and the method has good practical application value.

The invention relates to a medicinal composition, in particular to a composition comprising 4-hydroxyl-2-oxo-1-pyrrolidine acetamine and 2-borneol, and application of the composition in medicines for preventing and/or treating cognition impairment. The composition provided by the invention can remarkably improve a cerebral trauma neural function of a rat and can remarkably prolong the time of passive activities. The composition provided by the invention plays a role in improving dysmnesia of the rat, caused by scopolamine, and can remarkably improve cognitive disorder of the rat, caused by cerebral ischemia. The composition has a remarkable effect in preventing and/or treating cognition impairment.

The invention discloses bifidobacterium lactis Probio-M8 capable of relieving and improving symptoms of Alzheimer's diseases and applications thereof. APP/PS1 mice are taken as experimental subjects;7 mice whose genotypes are APP/PS1 are selected from the mice delivered through paired reproduction with wild mice; and after the random dividing of the mice into two groups, the bifidobacterium lactis Probio-M8 is poured into the stomach of the mice in one group, and normal saline is poured into the stomach of the mice in the other group, so that the changing of the number of A[beta] plaques in the brains of the mice can be determined. Through the proving of experimental results, the bifidobacterium lactis Probio-M8 has the effects of relieving and improving the symptoms of Alzheimer's diseases.

The invention relates to the field of gene engineering, and in particular relates to new LGI 1 gene mutation causing temporal lobe epilepsy (TLE) newly found in people and an application. The invention discloses the application of the 152nd gene locus A152G mutation of a first exon of an LGI 1 gene in preparation of a temporal lobe epilepsy co-disease depression animal model, and the application in screening of anti-temporal lobe epilepsy co-disease depression drugs. According to the invention, a homozygous model mouse with the gene mutation shows lethal epilepsy; an electroencephalogram of the heterozygous mouse can record epilepsy waveforms, and behavioristics shows that the mouse has co-disease depression; and the mouse can serve as new animal model of epilepsy co-disease depression andis used for mechanism research of epilepsy attack and epilepsy co-disease depression and research and development of anti-epilepsy combined depression drugs.

The invention belongs to the field of biological products, and relates to a composite vaccine for Alzheimer's disease prevention and treatment, wherein the composite vaccine is prepared by mixing a nucleic acid vaccine encoding Abeta42 and a protein gene engineering vaccine. Experiment results show that: Abeta42 protein antigen expressed through prokaryotic expression and pVAX-Abeta42 plasmid are adopted to co-immunize, such that the Alzheimer's disease protein vaccine in the prior art is improved, high level anti-Abeta antibody IgG can be produced, inhibition on T cell response can be induced, and the inhibition can be maintained for a fairly long time. In addition, the antibody generated through co-immunizing and for Abeta can be combined with Abeta protein fibers and nature Abeta protein precipitate in APP/PS1 Alzheimer's disease transgene incidence mice brain so as to provide Abeta precipitate removing capacity; and the vaccine is a potential, effective, and side effect-free vaccine, and can be used for Alzheimer's disease prevention and treatment.

The invention discloses a large and small mouse stereotaxic apparatus fixing structure, which comprises an operating plate, wherein the operating plate is connected with a fixing column through a regulation mechanism; the fixing column is provided with a tooth fixing mechanism; and the top of the operating plate is fixedly connected with two symmetrical fixing blocks a. The large and small mouse stereotaxic apparatus fixing structure has high regulation accuracy, and in a process that a large and small mouse is fixed, a situation that the teeth bleed or the eardrum is broken due to improper regulation can be avoided. The top of a supporting plate is provided with a magnet a and a magnet b so as to realize an effect that tissues or cloth liners can be conveniently fixed, and a situation that in a process that the large and small mouse receives a test, the large and small mouse suffers from gatism to pollute the supporting plate is avoided. The height of the supporting plate can be improved and reduced according to requirements so as to quickly fix the large and small mouse by an ear rod and a tooth fixing rod, and test efficiency is improved.

The invention provides a near-infrared A beta fluorescence imaging agent with high signal-noise ratio, as well as a preparation method and application thereof. An aggregation-induced emission dye hasa structure as shown in the formula I. In addition, the invention also provides application of the A beta fluorescence imaging agent in brain tissue slice fluorescent marking and living imaging. The tests show that the aggregation-induced emission dye provided by the invention has the advantages of near-infrared emission, high light stability, good biocompatibility, high signal-noise ratio and thelike, and can be used for accurately positioning an A beta plaque in an APP/PS1 transgenic mice brain tissue slice, so that the in-situ information such as the number of A beta plaques and real-timeform is acquired in a high fidelity way. Particularly, the imaging agent has favorable blood-brain barrier penetrability, and can be applied to in-vivo real-time imaging of the APP/PS1 transgenic micebrain A beta plaque. The formula I is shown in the description.

The present invention relates to a compound for preventing and treating cerebral apoplexy, particularly ischemic cerebral apoplexy, wherein the compound exhibits good therapeutic activity in a mouse cerebral ischemia reperfusion test, can significantly reduce the proportion of cerebral infarction, and can be used for preventing and treating cerebral apoplexy, particularly ischemic cerebral apoplexy.

The invention discloses a preparation method of an adult stem cell exosome and application thereof to treatment of Parkinson's disease, and belongs to the technical field of biomedicine. The preparation method comprises the steps that bone marrow mesenchymal stem cells, skin epidermis stem cells and adipose-derived stem cells are separated and cultured in vitro, exosomes in cell culture supernatants are extracted by an ultracentrifugation method, and the exosomes are administered by a nasal administration mode. The exosomes from the three sources can significantly relieve related symptoms of Parkinson's disease model mice, such as recovery of movement functions of the mice and increase of the number of dopaminergic neuronal cells at the black part in the brains of the mice.

The invention which relates to the biomedicine field discloses a mechanical separation method of neurons of adult mice. The method comprises the following steps: making the adult mice's brain tissue slices with the thickness of 350-375mum in an ice bath tissue culture solution with an electronic vibration slicer, preserving for 30-60min at room temperature, putting the brain tissue slices into a papain-containing tissue culture solution under aseptic conditions, controlling the temperature at 32.2-35.3DEG C, maintaining the temperature for 30min, placing the brain slices in a cell culture dish containing an HEPES buffer solution, selecting a neural region needing separation, and separating neurons through using a cell separator; and screening healthy neurons. The method of the invention, which allows a primary culture chemical separation method to be integrated into mechanical cell separation and the brain slices to be preprocessed with the papain, makes the healthy neurons of adult and aged mice to be obtained through the mechanical separation, and has the advantages of simplicity, convenience, and substantial separation effect.

The invention discloses interferon regulatory factor 9 (IRF9) and application of an inhibitor thereof in cerebral apoplexy, belonging to the field of gene function and application. The invention uses IRF9 gene knock-out mice and brain-specific IRF9 transgenic mice as experimental subjects and adopts middle cerebral artery ischemia reperfusion model, results show that compared with mild type C57 mouse, the brain infarction volume of IRF9 gene knock-out mouse is apparently inhibited, and nerve function is improve remarkably, while the infarction volume of nerve-specific IRF9 transgenic mouse is apparently inhibited, and nerve function is deteriorated markedly. Therefore, IRF9 gene has nervous system function deterioration effect; especially, IRF9 gene can deteriorate cerebral apoplexy. As for the above function of IRF9, the invention provides application of IRF9 as drug target of cerebral apoplexy treatment in developing medicaments for treating cerebral apoplexy.